开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2019-07-30 liuxd6

显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑

264 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2019-10-10 qmac

审稿速度:1.0 | 投稿命中率:25.0
经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志

344 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-12-10 ms6000001750417887 来自北京

一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗

158 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-04-14 ms4000000877142304

课题组的第二篇hepatology接收了。
贡献一个timeline；
11-nov-2021~21-dec-2021 reject with opportunity to resubmit
8-apr-2022 修回，当天主编直接 accept
总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。

227 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2024-03-26 Charls.Guo 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：肝硬化;预测模型
经验分享：肝病4大顶刊之一，有幸中了一篇。
贡献一个timeline；
07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit
5-Mar-2024 修回 - 24-Mar-2024 accept

73 0

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-06-20 1ddf3775m09(暂无匿称) 来自上海

Submission Received状态一般会持续几天？

143 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-05-13 川云不息来自浙江省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：临床转化;免疫;肝癌
经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域

127 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2020-05-14 xrkguoguo

想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。

292 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2019-02-05 半夜吹口哨

请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表:
2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

284 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=574207, encodeId=8d3e5e4207b4, content=显示with DE，投稿一星期了，还是Selecting/Assigning Reviewers，困惑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=264, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKd1Vhib4omj3zXo9z5JCjXtm6G91TkCDVZGtxwmtrpUficSbUlnxOtTV3b5ibwEIqBakVLU35OgIv9w/132, createdBy=f13d1958552, createdName=liuxd6, createdTime=Tue Jul 30 15:26:00 CST 2019, time=2019-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：今年有幸中了一篇，顺利毕业，很开心，总的来说，审稿速度非常快，投稿后两周返修，大修，修改了三个月后投回，一周后返修，三个审稿人只有一个审稿人有问题，没有补实验，只是进行了解释并投回，一周后接受，还是比较顺利的，三个审稿人的意见主要侧重于临床表型的方面，对机制要求并不高，但故事要完整，很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=344, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投，现在修回去了，但是刚提交几个小时状态就变成了reviews returned，有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1211188, encodeId=d3df12111887c, content=课题组的第二篇hepatology接收了。 贡献一个timeline； 11-nov-2021~21-dec-2021 reject with opportunity to resubmit 8-apr-2022 修回，当天主编直接 accept 总体而言，数据量要大且充实，论据充分，临床数据和动物数据都要有。这篇paper原本是投的nature cell biology后修稿被拒了就转头hepatology了。所以大问题没有什么，修改了一些细节然后就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=227, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=273b5376624, createdName=ms4000000877142304, createdTime=Thu Apr 14 17:11:50 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：肝硬化;预测模型 经验分享：肝病4大顶刊之一，有幸中了一篇。 贡献一个timeline； 07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit 5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2143963, encodeId=7e1f2143963d7, content=Submission Received状态一般会持续几天？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Tue Jun 20 22:10:19 CST 2023, time=2023-06-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2133663, encodeId=e3ec213366381, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床转化;免疫;肝癌 经验分享：中了一篇，杂志目前换了出版社，确实早该换了哈哈。编辑部审稿很认真，都是领域内的大牛。证据等级高的动物模型➕临床意义➕严密逻辑。基本可以发表。对具体的分子机制要求不高。而且我很喜欢的一点，美肝比欧肝关注的肝病种类齐全，包括肝脏发育，罕见门脉疾病等的研究很新也很有意思。不像欧肝过度关注肿瘤和脂肪肝领域, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhfUqNpOgohcD26YtsMB4dzdrdAcODsQXCHM8CWdlpRMZCELQRAUoRhUbc7IM13KbGgxtk9yPfHC8/0, createdBy=255d2107612, createdName=川云不息, createdTime=Sat May 13 23:00:34 CST 2023, time=2023-05-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用不知道是否包括legend。还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=292, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗？凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=284, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 小动量

方法的撰写顺序/逻辑顺序是什么？

242 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务